stockrow
Wednesday 11 November 2026
Export REPL’s income statement to Excel — free account
Replimune Group, Inc.
REPL- EPS
- +39.7%
- Free cash flow
- +42.2%
- Total debt
- +74.3%
Quarter to September 2026, against a year earlier
21.88
1.40
−6.01%
Follow REPL
Alert me
Replimune Group, Inc. (REPL) Current ratio
Replimune Group, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 7.1×, up 2.3× from fiscal 2026 (4.8×). Over the past ten years it has ranged from 4.8× (fiscal 2026) to 33.3× (fiscal 2021) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of 4.7× and above the Healthcare sector median of 3.2×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2026 | 4.8× | (39.72%) |
| FY2025 | 8.0× | (25.85%) |
| FY2024 | 10.7× | (38.79%) |
| FY2023 | 17.5× | (9.99%) |
| FY2022 | 19.5× | (41.47%) |
| FY2021 | 33.3× | 126.60% |
| FY2020 | 14.7× | 2.90% |
| FY2019 | 14.3× | 13.83% |
| FY2018 | 12.5× | 11.02% |
| FY2017 | 11.3× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 7.1× | 36.07% |
| Jun 2026 | 5.2× | 9.06% |
| Mar 2026 | 4.8× | (14.36%) |
| Dec 2025 | 5.6× | (11.28%) |
| 32 more quarters | Free account |
Against its own ten years
Low 4.8×
High 33.3×
Ten-year median
13.4×
Current reading's percentile
10
Current ratio against peers
| Company | Current ratio |
|---|---|
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 32.8× |
| IMNM Immunome, Inc. compare | 11.7× |
| VERA Vera Therapeutics, Inc. compare | 10.9× |
| TRAX First Tracks Biotherapeutics, Inc. compare | 9.2× |
| REPL Replimune Group, Inc. | 7.1× |
| VIR Vir Biotechnology, Inc. compare | 6.3× |
| AUPH Aurinia Pharmaceuticals Inc compare | 6.1× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 5.0× |
| ZYME Zymeworks Inc. compare | 3.3× |
| Biotechnology industry median | 4.7× |
| Healthcare sector median | 3.2× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)